Whole-exome sequencing
GeneticThe whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
NCT Number: NCT05317234
Cerebral palsy (CP) is a major neurodevelopmental disorder with an estimated prevalence of approximately one in 500 children. It is characterised by permanent developmental disorders of movement and posture, responsible for activity limitations, caused by non-progressive damage to the brain of the fetus, newborn or infant during development. The neurobiological mechanisms involved in CP remain poorly understood, although the interruption of cerebral oxygen supply during pregnancy or at the time of delivery is classically considered to be the main factor causing neurodevelopmental sequelae. CP also occurs in full-term infants without a clearly identifiable etiology.
Data from the literature suggest the existence of other pathophysiological processes than only acquired brain lesions related to pregnancy and delivery, such as genetic or epigenetic factors. According to some research teams, nearly one third of CP could have a genetic cause or could be favoured by genetic variants.
Preliminary research has made significant progress in revealing unusual copy number variants and/or mutations in single genes in children with CP. Several of the identified genes are involved in neurodevelopment and neuronal connectivity. Nevertheless, the identification of these abnormalities in CP may contribute to a better understanding of the pathophysiology of this complex and multifactorial disorder. It could also shed new light on the analysis of medico-legal files and bring encouraging perspectives by targeting new therapeutic interventions.
The main hypothesis is that a certain number of cerebral palsies are related to - or favoured by - genetic abnormalities that we will search for with genetic screening tests.
Interested in participating?
Request Info2 year–15 year
All sexes
Interventional
Not applicable
Service de Médecine Physique et Réadaptation Pédiatrique - Hôpital Femme-Mère-Enfant, Bron, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
Time frame: Until the end of study, an average of 4.5 years
Are considered positive for a significant genetic variant, patients for whom a or several class 4 or 5 variants have been identified, and explain the phenotype of pc. Genetic variants will be classified according to the recommendations of the American College of Genetics Medical (ACMG: American College of Medical Genetics) from 1 to 5.
Contact information is provided by the study sponsor or research team.
Cyril Huissoud, Pr
CONTACT
Fanny Joubert
CONTACT
Hospices Civils de Lyon
Other
Acronym: PREGENE PC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04096430
Autism Spectrum Disorder, Brain Damage, Chronic
Calgary, Alberta, Canada
View Trial DetailsNCT06111898
Brain Damage, Chronic, Brain Diseases
Geneva, Switzerland
View Trial DetailsNCT05907837
Brain Damage, Chronic, Brain Diseases
Cork, Ireland
View Trial DetailsNCT06645795
Brain Damage, Chronic, Brain Diseases
Valencia, València, Spain
View Trial Details